2014年2月14日，安斯泰来制药（Astellas Pharma）与AVEO Oncology宣布终止开发tivozanib的合作。tivozanib是AVEO Oncology开发的VEGFR抑制剂，2011年Astellas加盟该药的研发，虽然2011、2012连续被评为年度十大抗癌新药，但却屡战屡败。肾癌因为临床结果不一致被FDA拒绝，结肠癌在中期临床试验失败，三阴性乳腺癌因为患者数不够在II期终止。

2012年11月30日 AVEO Oncology与安斯泰来宣布，FDA接受tivozanib用于治疗晚期肾细胞癌的申请。根据双方签订的开发与商业化协议，AVEO将由安斯泰来处获得1500万美元的里程碑资金。

AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib

February 14, 2014

Phase 2 Colorectal Cancer Study Discontinued

AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014

Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC). The termination of the collaboration will be effective August 11, 2014 at which time tivozanib rights will be returned to AVEO. In accordance with the collaboration and license agreement, committed development expenses will be shared equally.  

“We would like to thank Astellas for its commitment to tivozanib and our partnership over the past three years,” said Tuan Ha-Ngoc, President and Chief Executive Officer of AVEO. “Given today’s announcements, we are re-aligning our resources behind key development opportunities to bring clinically meaningful treatments to patients and create shareholder value. We look forward to outlining our corporate strategy when we report our fourth quarter and full year 2013 results.”

“While our decision is based on strategic reasons, Astellas is proud of our partnership and work with AVEO,” said Yoshihiko Hatanaka, President and CEO of Astellas. “We remain committed to the field of Oncology to help meet the unmet needs of cancer patients.”    

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除